Nontuberculous Mycobacterial Lung Disease: Strategies and Solutions for Real-World Management

To participate in this activity, please:

Nontuberculous mycobacteria (NTM) represent more than 200 species and subspecies, some of which can produce chronic infection in the lungs and other organs. Among the NTM, Mycobacterium avium complex (MAC) is the most prominent. Guidelines issued in 2020 are helpful to guide the management of patients with NTM lung disease (NTM-LD). Nonetheless, care is highly individualized through collaboration by an interprofessional team of experienced clinicians. In this case-based activity, our expert faculty provide their insight to address challenges encountered in everyday clinical practice. Their discussion highlights real-world best practices in diagnosis and treatment initiation and modification based on guideline recommendations for MAC-LD, recent scientific and therapeutic advances, strategies for optimizing treatment adherence and completion, and the importance of shared decision-making with interprofessional collaborative care. 

Course Credit:

1.5 ACPE Contact Hours
1.5 AMA PRA Category 1 CreditsTM
1.5 ANCC Contact Hours


Opens: 2022-08-31
Closes: 2023-08-31

Target Audience:

This activity was developed for pulmonologists, infectious disease specialists, nurse practitioners, nurses, pharmacists, and other clinicians who have a role in the diagnosis and treatment of patients with nontuberculous mycobacterial lung disease.

This activity is supported by an Educational Grant from Insmed.

    Presenting Faculty

  • Jennifer Faber-Gerling, RN, MS, CNS, NP-BC

    Division of Mycobacterial and Respiratory Infections
    National Jewish Health
    Denver, Colorado

  • David E. Griffith, MD

    Professor of Medicine
    National Jewish Health
    Denver, Colorado

  • Christina O'Connor, PharmD, BCPS, AAHIV-P

    Antimicrobial Stewardship Clinical Pharmacist Manager
    Assistant Professor of Pharmacy
    Mayo Clinic College of Medicine and Science
    Rochester, Minnesota